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Abstract
Scale-up of viral load (VL) monitoring for HIV-infected patients on antiretroviral therapy (ART) is 
a priority in many resource-limited settings, and ART providers are critical to effective program 
implementation. We explored provider-perceived barriers and facilitators of VL monitoring. We 
interviewed all providers (n=17) engaged in a public health evaluation of dried blood spots for VL 
monitoring at five ART clinics in Malawi. All ART clinics were housed within district hospitals. 
We grouped themes at patient, provider, facility, system, and policy levels. Providers emphasized 
their desire for improved ART monitoring strategies, and frustration in response to restrictive 
policies for determining which patients were eligible to receive VL monitoring. Although many 
providers pled for expansion of monitoring to include all persons on ART, regardless of time on 
ART, the most salient provider-perceived barrier to VL monitoring implementation was the 
pressure of work associated with monitoring activities. The work burden was exacerbated by 
inefficient data management systems, highlighting a critical interaction between provider-, 
facility-, and system-level factors. Lack of integration between laboratory and clinical systems 
complicated the process for alerting providers when results were available, and these 
communication gaps were intensified by poor facility connectivity. Centralized second-line ART 
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distribution was also noted as a barrier: providers reported that the time and expenses required for 
patients to collect second-line ART frequently obstructed referral. However, provider 
empowerment emerged as an unexpected facilitator of VL monitoring. For many providers, this 
was the first time they used an objective marker of ART response to guide clinical management. 
Providers’ knowledge of a patient's virological status increased confidence in adherence 
counseling and clinical decision making. Results from our study provide unique insight into 
provider perceptions of VL monitoring and indicate the importance of policies responsive to 
individual and environmental challenges of VL monitoring program implementation. Findings 
may inform scale-up by helping policymakers identify strategies to improve feasibility and 
sustainability of VL monitoring.
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Introduction
Viral load (VL) testing is recommended by the World Health Organization (WHO) as the 
preferred method for monitoring response to antiretroviral therapy (ART) and identifying 
treatment failure(WHO, 2013). Alternative methods for identifying treatment failure in 
resource-limited settings, such as immunological (CD4 cell counts) and clinical staging, are 
considerably less sensitive and specific than VL monitoring (Chaiwarith et al., 2007; Mee, 
Fielding, Charalambous, Churchyard, & Grant, 2008; Moore et al., 2008; Rawizza et al., 
2011; Rewari et al., 2010; Reynolds, Nakigozi, et al., 2009; Sigaloff et al., 2011; van 
Oosterhout et al., 2009). By identifying failure earlier, VL monitoring reduces morbidity and 
mortality, improves second-line ART outcomes by avoiding accumulation of ART resistance 
mutations, and guides providers as they counsel patients and reinforce adherence behavior 
(Anderson & Bartlett, 2006; Calmy et al., 2007; Gsponer et al., 2012; Hosseinipour et al., 
2009; Keiser et al., 2010; Kumarasamy et al., 2009; Marconi et al., 2008; Pujades-
Rodriguez, O'Brien, Humblet, & Calmy, 2008; Reynolds, Kityo, et al., 2009). Despite these 
benefits, VL monitoring is rarely available in, resource-limited settings with the highest HIV 
burden, including sub-Saharan Africa. Traditional VL tests require expensive laboratory 
equipment, complex specimen collection procedures, and highly-trained personnel (Calmy, 
et al., 2007; Roberts, Bygrave, Fajardo, & Ford, 2012; UNAIDS, 2013). Dried blood spots 
(DBS) have emerged as an alternative to plasma-based VL testing for resource-limited 
settings by simplifying specimen collection and storage; centralizing laboratory testing; and 
reducing the need for extensive clinic-level laboratory infrastructure. DBS collection by 
ART providers at outlying clinics and a centralized laboratory for specimen testing may 
increase access to VL monitoring in remote clinics (Johannessen, 2010; Johannessen, 
Troseid, & Calmy, 2009; Rutstein et al., 2015). The WHO and national ART management 
guidelines in many resource-limited settings advocate use of DBS as the preferred 
monitoring model when traditional VL testing is not feasible (“Clinical Management of HIV 
In Children and Adults,” 2014; WHO, 2013, 2014).
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ART providers are critical to the WHO phased approach to VL scale-up preparations 
(Figure 1) (WHO, 2014) and, ultimately, to achieve potential individual and public health 
benefits of VL monitoring. Currently, providers are responsible for clinical staging, 
adherence counseling, and drug distribution. VL monitoring may task providers with 
additional responsibilities, including VL specimen collection and providing focused 
adherence counseling and more frequent second-line ART referral. Appropriate counseling 
and referral for second-line ART requires provider commitment and cooperation, as well as 
adequate comprehension of how to deliver guideline-concordant care using VL monitoring 
results(Madec, Leroy, Rey-Cuille, Huber, & Calmy, 2013).
Recognizing that successfully implementing and sustaining a VL monitoring program 
requires ART providers’ support, we interviewed providers to explore their perceived 
barriers to, and facilitators of, incorporating VL monitoring into daily clinical practice. 
These interviews were conducted in the context of a parent study in which we evaluated the 
feasibility and effectiveness of DBS for VL monitoring in ART clinics in central and 
southern Malawi (Rutstein, et al., 2015). Less than 1% of Malawian ART patients are on 
second-line regimens, likely a reflection of providers’ reliance on clinical staging to identify 
first-line treatment failure (“Integrated HIV Program Report July - September 2013,” 2013). 
Responding to WHO policies and the likely under-diagnosis of virological failure, Malawi is 
one of many countries attempting to incorporate VL monitoring from DBS into its care 
package for the 450,000+ persons on ART, phasing out the still limited CD4-cell count 
based monitoring approach (“Clinical Management of HIV In Children and Adults,” 2014). 
Findings may help inform VL monitoring scale-up strategies, focusing on the contributions, 




The parent study was a public health evaluation of DBS for VL monitoring at five ART 
clinics located in district hospitals in central and southern Malawi (Rutstein, et al., 2015). 
None of the enrolling clinics had access to VL monitoring outside of enrollment in the DBS 
study; all clinics relied on clinical staging for ART monitoring as CD4-based criteria was 
not recommended per Malawi guidelines in place during the period of data collection 
(2013-2014) (“Clinical Management of HIV In Children and Adults,” 2014). (S. Rutstein, D. 
Kamwendo, et al., 2014; S. E. Rutstein et al., 2014)Target study enrollment ranged from 
250-450 ART patients, depending on clinic size and pace of enrollment (Table I). Clinics 
were staffed by a combination of nurses, clinical officers, and other ART support staff, 
although daily staff frequently rotated. All providers received a two-day training on study 
protocols (Figure 2). VL results were returned to the clinic using a combination of e-mail, 
short message service (SMS), mobile phone, and hand-delivered hardcopy results. To retain 
confidentiality, SMS and email messages identified patients using only unique patient 
identifiers.
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Study Population and Activities
Between July 2013 and January 2014, we conducted in-person interviews with all providers 
involved in the parent study clinical activities at enrolling clinics. Providers’ VL monitoring 
responsibilities included retrieving patient records, collecting specimens, arranging transport 
of specimens to the central laboratory, communicating with the study team regarding supply 
shortages, patient adherence counseling after receiving VL results, and second-line ART 
referral. We identified providers via onsite point-persons–frequently a nurse who assumed 
additional study-related duties(Marshall, 1996). All providers agreed to participate and gave 
written informed consent. The National Health Sciences Research Committee of Malawi, the 
Centers for Disease Control and Prevention Ethics Review, and the Biomedical Institutional 
Review Board at University of North Carolina, Chapel Hill approved this study.
Interview guide
We developed the interview guide to explore providers’ perceptions of the barriers and 
facilitators to implementing VL monitoring. We used probing questions to explore emerging 
themes. All interviews were conducted in English by two study coordinators who had no 
affiliations within enrolling clinics. Interviewers were trained in qualitative methods and 
contributed to development of the interview guides. Interviews were audio-recorded and 
transcribed (Corbin & Strauss, 2008; Marshall, 1996).
Analysis
All transcripts were coded by the primary researcher (SER) using ATLAS.ti (version 7.0, 
ATLAS.ti Scientific Software Development GmbH, Berlin, Germany) (Friese, 2014). A 
second coder (SH), independently coded 30% of transcripts. The two coders reviewed 
double-coded transcripts; differences in code application were resolved through discussion 
and negotiated consensus (Corbin & Strauss, 2008; Yin, 2011).
We based initial structural codes upon interview topics (e.g., specimen handling, returning 
VL results to clinic). Thematic content analysis of transcripts guided identification, analysis, 
and reporting of themes (Braun & Clark, 2006). We reviewed transcripts for broad concepts 
and used early memos to generate an initial codebook (Saldana, 2013). As we identified 
interpretive codes, we coded in more depth, revising and accumulating codes (Boeije, 2002). 
We added new themes to the codebook and reviewed previously-coded transcripts to ensure 
coding logic completeness and consistency. The codebook was therefore a living document–
adapting to the themes and concepts as they surfaced during analysis. When we completed 
the coding, we conducted a line-by-line analysis to ensure that all coded transcripts reflected 
the final codebook.(Saldana, 2013)
Results
Participant characteristics
We interviewed 17 ART providers: 3 ART coordinators, 8 non-coordinator nurses, and 6 
other clinic personnel. ART coordinators were either nurses or clinical officers (non-
physician clinical provider). Other providers included a hospital attendant, laboratory 
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technicians (n=2), HIV testing counselors (n=2), and an ART clerk. Providers had been in 
their posts a median of 7 years (range 1-30).
Overview of provider-reported barriers and facilitators
We identified 12 themes at five levels: patient-level (demand for VL monitoring, financial 
barriers to VL monitoring uptake, comprehension of VL), provider-level (benefits of VL 
monitoring, workload), facility-level (specimen handling, communication, staffing and task 
distribution), system-level (delayed result return, second-line ART distribution), and policy-
level (eligibility restrictions, continuation of VL monitoring post-study completion) (Figure 
3). We present results at each level, examining the interplay between levels and themes in 
the discussion.
Patient-level factors: ‘in my body’—Providers characterized an eager patient 
population that craved information about their body's response to ART. This eagerness was 
countered both patients’ and providers’ frustration with the Ministry of Health's (MOH) 
eligibility criteria for receiving VL testing (Table 2, Patient [1]).
Despite eagerness for VL monitoring, providers identified common patient-reported 
including challenges with attending follow-up visits to both receive results and be referred 
for second-line therapy. To facilitate faster transition to appropriate regimens for failing 
patients, the study protocol dictated patients return after one month to receive VL results – 
an extra trip between the normal quarterly clinic visits. Some providers claimed that patients 
were willing to follow-up, while others emphasized patient reluctance to return between 
their regularly scheduled visits. On rare occasions, providers reported that eligible patients 
declined monitoring because of financial barriers associated with acquiring transportation 
for the extra visit back to the clinic to receive results (Table 2, Patient [2]).
Providers described a spectrum of patients’ comprehension of VL. The overwhelming 
majority of providers reported that patients understood the concept of VL. However, other 
providers reported patients confusing VL with CD4 cell counts or described dangerous 
misunderstandings regarding interpretation of an “undetectable” VL (Table 2, Patient [3]).
Providers frequently used patient misconceptions as an opportunity to counsel on the 
importance of ART adherence.
Provider-level factors: ‘pressure of work’—All providers identified benefits for both 
patients and providers of incorporating VL into clinical practice. Patient education, 
including reinforcing adherence behavior, was frequently identified as a benefit of delivering 
the VL result (Table 2, Provider [1]).
Another reported benefit of VL monitoring was helping providers identify treatment failure. 
Clinical symptoms poorly predict virological failure (Chaiwarith, et al., 2007; Lynen, Van 
Griensven, & Elliott, 2010; Mee, et al., 2008; Moore, et al., 2008; Rawizza, et al., 2011; 
Reynolds, Nakigozi, et al., 2009; van Oosterhout, et al., 2009). However, in the absence of 
VL monitoring, providers relied on the less sensitive and less specific clinical staging to 
identify ART failure. Providers were surprised at how infrequently the patients with high 
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VLs showed symptoms of failure, expressing concern that they may have missed persons 
who were failing treatment (Table 2, Provider [2]).
Provider empowerment emerged as an unexpected reported benefit of VL monitoring. Most 
providers had not used VL to guide ART management previously. Although familiar with 
ART's mechanism of action, this was the first time many providers directly appreciated ART 
suppressing viral replication. The evidence of ART efficacy increased provider's confidence 
in ART adherence counseling and contributed to their overall clinical confidence. Providers 
frequently expressed excitement with their new insight into patient well-being (Table 2, 
Provider [3,4]).
Despite the acknowledged benefits of VL monitoring, providers emphasized that the 
associated duties overwhelmed already-limited personnel. Every provider involved in patient 
management described the additional burden associated with VL monitoring, such as the 
time required to complete adherence assessment forms. It was unclear whether the added 
work burden was specific to study activities (e.g., obtaining patient consent) or extended to 
tasks that would be expected of providers if VL monitoring was integrated into their 
everyday clinical practice (Table 2, Provider [5]).
Facility-level factors: ‘disconnected’—Providers were generally pleased with sample 
collection and storage of DBS cards(Johannessen, 2010; Johannessen, et al., 2009). Among 
providers who described specimen collection as part of their study duties, most 
acknowledged the simple and rapid (~3-5 minutes) fingerstick specimen collection 
procedures. However, when challenges with specimen collection were noted, they were 
frequently due to cool weather or thickened skin (Table 2, Facility [1]).
Inconsistent specimen transport mechanisms hindered DBS specimen movement between 
outlying clinics and the central laboratory. The parent study relied largely on hospital 
vehicles for specimen transportation. Site personnel were instructed to work with the 
hospital administrators and other departments to arrange for DBS cards to go with any 
vehicle going from the hospital to the capital, located approximately 3-6 hours from 
enrolling clinics. Although generally described as successful, providers noted inconsistent 
availability of vehicles to facilitate specimen transfer (Table 2, Facility [2]). The hospital 
that used an established district-wide motorcycle specimen transport system was more 
satisfied with their specimen transfer arrangements.
Absent/intermittent internet connectivity interrupted communication between the central lab 
and clinics. Communication about results, need for additional supplies, or other VL 
monitoring-related issues frequently relied on personal mobile phones. This barrier was 
generally identified by the clinic “point person” who had been tasked with oversight of 
supplies and recording VL results (Table 2, Facility [3]).
Perhaps the greatest facility-specific barrier to VL monitoring was the shortage of staff, an 
issue frequently identified as an impediment to completing VL monitoring activities (Table 
2, Facility [4]). Rotating staff further obstructed VL enrollment and follow-up activities. 
Providers described inconsistent staffing alongside reluctance of rotating staff to participate 
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in VL monitoring activities as contributors to failing to return VL results to patients during 
scheduled clinic visits (Table 2, Facility [5]).
Some sites were able to accommodate the extra responsibilities better than others, largely 
due to more equitable distribution of tasks. Interestingly, providers who identified teamwork 
as key to their success were exclusively at higher volume sites – none of the low-volume site 
providers discussed teamwork during interviews (Table 2, Facility [6]).
Task-shifting to lower-cadre providers, such as health surveillance assistants (HSAs), 
occurred at most sites. Task-shifting helped distribute the burden of VL monitoring 
activities, particularly specimen collection, (Callaghan, Ford, & Schneider, 2010; Chan et 
al., 2014; Pannus et al., 2014) and facilitated access to VL monitoring in more remote clinics 
and health centers where nurses and clinicians may not rotate regularly.
System-level factors: ‘at first, it was difficult’—Delayed return of VL results to 
patients and centralized second-line ART distribution inhibited patient flow and referral 
efficiency. A month-long machine outage at the central lab created a backlog in completing 
assays and required rescheduling numerous patient follow-up visits. Unfortunately, without 
an established notification system, patients still came to the clinic despite unavailable 
results. Also, as neither electronic nor paper-based data management systems could alert 
providers when a result was sent by the laboratory, providers frequently missed opportunities 
to deliver results even when they were available. Providers at all clinics highlighted 
laboratory-driven delays, citing discrepancies between result turnaround times the lab 
projected versus provided (Table 2, System [1]). When probed further on reasons that 
results had not been delivered months after a patient was enrolled, a few providers focused 
on patients, suggesting that patients should remind providers when they were expecting a 
result.
Most providers endorsed the idea of using of an SMS printer to facilitate more rapid result 
reporting. SMS printers are distinct from the mobile-phone based SMS method used in this 
study. SMS printers could receive data directly from the central laboratory, generating a 
receipt-like output containing patient ID and VL results (Table 2, System [2]).
Providers reported that the time and expenses required for patients to collect second-line 
ART frequently obstructed referral. Second-line ART distribution is tightly controlled in 
Malawi and frequently only available at larger district or central hospitals. Half of the 
patients who were eligible for second-line ART were switched the same day they received 
their confirmatory VL result. However, providers described tremendous challenges linking 
the remaining patients to second-line therapy. For some patients, it took over a year before 
they started on second-line ART (Table 2, System [3,4]).
Policy-level factors: ‘why not us?’—Reported policy factors highlight the challenges 
of practising in extremely resource-constrained settings where care rationing confronted the 
desire to provide comprehensive services to patients. For example, Malawi policy dictates 
that persons are eligible for VL monitoring after 6- and 24-months of ART exposure, and 
every 24-months thereafter, or if they are showing clinical signs of treatment failure 
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(“Clinical Management of HIV In Children and Adults,” 2014). Providers were frustrated 
with criteria that required them to turn away many willing patients who had been on ART 
for years but were not presenting at an eligible time point. They were forced to ration a 
service that they felt was tremendously useful for guiding clinical practice and counseling 
patients. Perceived rationing of this ART management tool challenged providers’ newfound 
empowerment. Relaying the response of patients who failed to meet eligibility criteria, 
providers almost universally described a patient sentiment of ‘why not us?’ (Table 2, Policy 
[1]).
At the end of each interview, providers were given the opportunity to ask any questions and 
provide feedback regarding study procedures (i.e., what worked? What could be improved?). 
Providers frequently queried about plans for continuing VL monitoring activities after 
meeting study enrollment targets (Table 2, Policy [2]).
Discussion
Successful implementation of VL monitoring in resource-limited settings requires 
coordination of, and buy-in from, numerous stakeholders, especially ART providers. We 
interviewed all providers engaged in a public health evaluation of DBS for VL monitoring in 
Malawi. We identified a complex set of interconnected provider-identified barriers and 
facilitators to VL monitoring that occurred at multiple levels.
Patients’ demand for VL testing reinforced the provider-perceived benefits of monitoring. 
Provider empowerment emerged as an unexpected facilitator. For many providers, the DBS 
study was the first time they used an objective marker of ART response to guide clinical 
management. Providers’ knowledge of a patient's virological status increased confidence in 
adherence counseling and clinical decision making. Emphasizing provider empowerment 
during VL scale-up activities may increase providers’ willingness to adopt additional 
responsibilities. Our results suggest that VL monitoring can modify provider behavior and 
should be presented as a tool to help providers improve the quality of HIV care they deliver 
to patients.
Despite reported benefits of VL monitoring, new clinician responsibilities are often met with 
uncertainty or resistance (Arnold et al., 2012; Krakower, Ware, Mitty, Maloney, & Mayer, 
2014; Lester et al., 2010), particularly in inadequately staffed clinics. Human resource 
capacity among clinical health care workers is a key consideration in VL monitoring 
implementation in resource-limited settings(WHO, 2014). Task-shifting to lower-cadre 
health workers could redistribute current responsibilities, especially with non-phlebotomy-
based specimen collection (i.e., fingerstick DBS cards) (Callaghan, et al., 2010; Pannus, et 
al., 2014; S. E. Rutstein, et al., 2014). Our results suggest task-shifting only for specimen 
collection will be insufficient as providers’ frustration with workload frequently focused on 
data management, patient counseling, and patient referral. Given the time constraints 
reported by providers, expanding provider-to-patient ratios at ART clinics, broadening the 
scope of practice, and training lower-cadre health workers may facilitate program 
sustainability.
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To harmonize facility-, system-, and policy-level interactions (Figure 1, Figure 3) (WHO, 
2014), shortcomings in data management systems need to be overcome. Lack of integration 
with centralized laboratory systems complicated the process for alerting providers when 
results were available; these communication gaps were exacerbated by poor internet 
connectivity. The delays in result availability frustrated providers and patients. These 
obstacles could be addressed by point-of-care VL technologies, but such devices are still 
years from meeting standards for widespread use (“Point-of-Care Implementation 
Guidelines: Directing Scale-up of Point-of-Care Testing for HIV-related Diagnostics in 
Malawi,” 2012; Reid, Fidler, & Cooke, 2013; Usdin, Guillerm, & Calmy, 2010; WHO). 
Improving coverage of mobile networks and increasing internet connectivity to outlying 
clinics will be critical to maintain reliable clinic-laboratory communication, and crucial for 
the success of the centralized VL monitoring model.
In contrast to centralized laboratories, decentralized drug distribution will be imperative for 
effective patient referral and initiation of second-line ART. For many patients, the cost and 
inconvenience of travelling to a central distribution point considerably delayed initiation of 
second-line therapy, especially because initiation on second-line drugs requires monthly 
clinic visits for at least six months(“Clinical Management of HIV In Children and Adults,” 
2014). VL monitoring will likely increase the proportion of patients initiating second-line 
therapy(S. Rutstein, M. C. Hosseinipour, et al., 2014). Decentralized second-line ART 
distribution should be considered with any scale-up of VL monitoring, along with supply 
chain procedures to minimize stock-outs.
Another system-wide policy that discouraged patients and providers was the MOH's strict 
monitoring eligibility criteria (“Clinical Management of HIV In Children and Adults,” 
2014). Patients craved information regarding their VL, and providers were frustrated as they 
were forced to ration testing based on restrictive policies. Many providers pleaded for 
expanded VL monitoring eligibility. Anticipating these frustrations, policymakers should 
design provider trainings and patient education materials explaining that the criteria were 
designed to optimize access to extremely limited VL monitoring opportunities for patients at 
highest risk of ART failure(“Clinical Management of HIV In Children and Adults,” 2014; 
WHO, 2013). Another option is “catch up” testing, where every patient on ART for greater 
than two years receives a single test, and then returns to the biannual eligibility. Extended 
unmonitored exposure to ART is associated with increased risk of virological failure, even in 
the absence of clinical symptoms (S. Rutstein, M. C. Hosseinipour, et al., 2014). A “catch 
up” approach might satisfy providers and patients and improve detection of virological 
failure.
Generalizability of the provider experience must be evaluated against the backdrop of the 
parent study. Perceptions of activities for a study may differ from standard clinical 
procedures, particularly regarding provider-perceived work burden. Although we restricted 
data collection responsibilities to mimic real-world implementation, completing study forms 
and procedures may have contributed to frustrations with workload. Furthermore, all study 
sites were ART clinics associated with district hospitals: providers staffing more remote 
health centers may encounter a different set of barriers to VL monitoring. ART patients at 
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more isolated ART clinics may need to travel further to receive care, emphasizing the 
importance of decentralized distribution of second-line drugs.
We believe ours is the first study to investigate provider perceptions of implementing VL 
monitoring in resource-limited settings. We offer insights into the multi-level barriers to, and 
facilitators of, VL monitoring from providers who serve on the frontline of ART 
management. We observed demand from both patients and providers for more widespread 
and inclusive VL testing. The most salient provider-reported barrier to VL monitoring 
implementation was the workload associated with monitoring activities, taxing an 
overextended provider workforce. Provider empowerment from using laboratory results to 
focus adherence counseling and guide clinical management was a striking facilitator of VL 
monitoring. Our results are exploratory, but may help decision-makers design programs that 
anticipate provider-reported barriers and facilitators, helping to anticipate obstacles and take 
advantage of identified opportunities to improve feasibility and sustainability of VL scale-
up.
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Figure 1. WHO VL Monitoring Scale-up(WHO, 2014)
Phased implementation of viral load monitoring as described in the World Health 
Organization's Technical and Operational Considerations for Implementing HIV Viral Load 
Testing identifies human resources, including training ART providers, in Phase II of the 
scale-up activities.
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Figure 2. Dried blood spot (DBS) study flow
ART patients receiving care at enrolling clinics were briefed as to study purpose and 
eligibility during the morning education section. After identifying eligible patients, 
providers completed informed consent forms and study-specific case report forms for patient 
demographics, clinical history, and adherence. DBS specimens were collected and, after 
appropriate drying time, transported to the central laboratory in Lilongwe where specimens 
were tested. Results were returned to clinics using email, SMS and/or in-person hard-copy 
printouts. Patients were supposed to receive the results at their next visit. Each site was 
encouraged to designate tasks and responsibilities to clinic personnel in a manner that suited 
existing clinic flow, patient volume, and staffing constraints. The provider interviews, the 
topic of this paper, occurred once the study procedures had begun at a given clinic.
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Figure 3. Multilevel framework
This figure outlines the multilevel factors that relate to provider acceptability, perceived 
barriers and facilitators of viral load (VL) monitoring using DBS. The framework identified 
patient, provider, facility, system and policy factors that are examined in our assessment of 
barriers to and facilitators of incorporating VL monitoring into clinical practice. ART, 
antiretroviral therapy; B, barrier; DBS, dried blood spot; F, facilitator
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